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ABSTRACT
Type 1 diabetes mellitus (T1DM) is associated with chronic complications that lead to high morbid-
ity and mortality rates in young adults of productive age. Intensive insulin therapy has been able to 
reduce the likelihood of the development of chronic diabetes complications. However, this treatment 
is still associated with an increased incidence of hypoglycemia. In patients with “brittle T1DM”, who 
have severe hypoglycemia without adrenergic symptoms (hypoglycemia unawareness), islet trans-
plantation may be a therapeutic option to restore both insulin secretion and hypoglycemic percep-
tion. The Edmonton group demonstrated that most patients who received islet infusions from more 
than one donor and were treated with steroid-free immunosuppressive drugs displayed a consider-
able decline in the initial insulin independence rates at eight years following the transplantation, but 
showed permanent C-peptide secretion, which facilitated glycemic control and protected patients 
against hypoglycemic episodes. Recently, data published by the Collaborative Islet Transplant Regis-
try (CITR) has revealed that approximately 50% of the patients who undergo islet transplantation are 
insulin independent after a 3-year follow-up. Therefore, islet transplantation is able to successfully 
decrease plasma glucose and HbA1c levels, the occurrence of severe hypoglycemia, and improve pa-
tient quality of life. The goal of this paper was to review the human islet isolation and transplantation 
processes, and to describe the establishment of a human islet isolation laboratory at the Endocrine 
Division of the Hospital de Clínicas de Porto Alegre – Rio Grande do Sul, Brazil. Arch Endocrinol Metab. 
2015;59(2):161-70
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T ype 1 diabetes mellitus (T1DM) is responsible for approximately 10% of all diabetes cases worldwide. 
This disease is caused by autoimmune destruction of 
pancreatic β cells, which leads to complete insulin de-
ficiency and fates patients to require exogenous insulin 
to survive (1,2). Although significant advances in the 
treatment of T1DM have been seen in recent decades 
(3,4), this disease still leads to chronic complications, 
which are associated with high morbidity and mortal-
ity in individuals in a productive age (5). Moreover, a 
number of T1DM patients present “brittle T1DM”, 
which is characterized by unpredictable glycemic os-
cillations over short periods of time, with sudden epi-
sodes of hyperglycemia followed by severe hypoglyce-
mia, which may evolve to convulsions, coma, and even 
death (6). The “brittle T1DM” treatment still repre-
sents a major challenge for the clinicians, and there is 
no consensus indicating the optimal treatment for this 
condition. The replacement of β cells through whole-
pancreas or islet transplantation is the only manner to 
restore endogenous insulin secretion and the awareness 
of hypoglycemic symptoms and represents an appealing 
treatment option for these patients (7,8).
Whole-pancreas transplantation results in adequate 
glycemic control and is able to prevent diabetic chronic 
complications, being recommended for T1DM patients 
with end-stage kidney disease, at the same time as the 
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transplanted patients show high rates of long-term 
survival, this procedure is usually not recommended 
to T1DM patients who do not require a kidney trans-
plantation, since its morbidity and mortality rates are as 
high as those associated with other major surgical pro-
cedure (7,9,10). In this context, allogeneic islet trans-
plantation has become an interesting option for “brittle 
T1DM” patients, as it consists of a cell infusion pro-
cedure, which is not associated with major complica-
tions. This occurs because the islets are infused directly 
into the liver through the portal vein (Figure 1) using 
interventional radiology techniques (7). According to 
the Collaborative Islet Transplant Registry (CITR), the 
risk of peri-procedure complications associated with is-
let infusion is 20 times lower than that observed after 
whole-pancreas transplantation (11). 
Therefore, the aim of the present study was to re-
view the current literature regarding pancreatic islet 
isolation and transplantation in T1DM patients as well 
as evaluate the current status of this procedure in the 
international health scenario. Furthermore, we also 
described the development of a laboratory for human 
pancreatic islet isolation in the Endocrine Division 
of the Hospital de Clínicas de Porto Alegre (HCPA; 
Porto Alegre, Brazil). Currently, this laboratory is 
equipped and technically prepared to begin islet trans-
plantation in T1DM patients who underwent kidney 
transplantation. 
HISTORICAL ASPECTS
Although pancreatic islet transplantation was first at-
tempted in 1893 (12), it was only in 1972 that Lacy 
and cols. (13) managed to reverse hyperglycemia in 
diabetic rodents through the infusion of healthy islets. 
In the 1980s, the use of autologous islet transplanta-
tion in patients who underwent total pancreatectomy 
for untreatable pain as a result of chronic pancreatitis 
was reported (14). These patients were able to main-
tain insulin independence for up to 13 years following 
the transplant (15). Since these data were first pub-
lished, the use of islet transplantation for the treatment 
of T1DM has been investigated by several researchers, 
who sought a possible cure for this condition. 
 Nevertheless, the first attempts at allogeneic pan-
creatic islet transplantation in humans did not produce 
promising results, leading to insulin independence 
rates of only 10% (16,17). Data obtained from the Is-
let Transplant Registry (ITR) revealed that a total of 
493 islet transplantations were performed worldwide 
between the years 1893 and 2000, showing decreasing 
rates of insulin independence over the time following 
the transplant: 66% after 1 month, 40% after 1 year, 
22% after 2 years, 11% after 3 years, 6% after 4 years and 
only 2% after 5 years (18). Although semi-automated 
islet isolation was made possible in 1989 by the research 
group led by Dr. Camillo Ricordi, in Miami, USA (19), 
it was only in the year 2000, after the creation of the 
Edmonton protocol, that islet transplantation began 
to achieve more promising results: an insulin inde-
pendence rate of 100% was achieved after 1 year post 
transplant in seven patients with T1DM (20). The im-
provement in achieving insulin-independence with this 
protocol was attributed to the following factors: use of 
corticoid-free immunosuppressive protocols (induction 
with daclizumab and maintenance with sirolimus and 
a low dose of tacrolimus), and multiple islet infusions 
from different donors, in order to increase the mass of 
transplanted islets (20). In 2005, the same group pub-
lished the results of a five-year follow-up of 65 patients 
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who had undergone islet transplantation. The mean 
duration of insulin independence was 15 months, with 
only 10% of patients remaining insulin-free for more 
than 5 years (21). However, it is important to note that 
80% of patients had partial graft function, with detect-
able C-peptide secretion, contributing to the improve-
ment of glycemic control and to the reduction in the 
number of hypoglycemic episodes.
The Edmonton protocol was later replicated in a 
multicenter study organized by the Immune Toler-
ance Network, which involved 36 patients with T1DM 
from nine centers in the USA and Europe (22). Only 
13.8% of patients remained insulin-free after 2 years, 
although those who maintained partial graft function 
had a substantial improvement in metabolic control 
and significant lower rates of hypoglycemia (22). Suc-
cess rates varied widely between centers, so that those 
with greater experience in the area obtained the best 
results, with approximately 80% of patients maintaining 
insulin independence after one year (22). These find-
ings led to a new definition of the objectives and out-
comes associated with islet transplantation. The main 
goal of islet transplantation is insulin independence 
and, therefore, procedures are considered completely 
successful whenever this outcome is achieved. How-
ever, when the transplant leads to improved glycemic 
control and to the reduction or elimination of severe 
hypoglycemic episodes, even if exogenous insulin use is 
still required in low doses, the procedure is considered 
partially successful. Individuals with partial graft func-
tion (defined by C-peptide levels > 0.5 ng/mL) main-
tained their glycemic control much better than those 
with total graft loss (absence of C-peptide secretion) 
(HbA1c: 6.7 vs. 9.0%, P = 0.025) and required signifi-
cantly lower doses of insulin following the transplant 
than in the pre-transplant period (0.34 vs. 0.66 insulin 
units/kg/day, P = 0.001), as demonstrated in a five-
year follow-up study (21).
These encouraging results led to a significant in-
crease in the number of islet transplantations performed 
in all existing research centers, and motivated the es-
tablishment of further transplantation centers around 
the world (http://citregistry.org). The CITR was also 
created in an attempt to monitor the progress of islet 
transplantation technology and to ensure greater safety 
in such procedures through the registration, analysis 
and publication of data regarding all islet transplanta-
tion performed in North America as well as in some 
European and Australian locations. A total of 76 cen-
ters conducted islet transplantation in the year 2005 
(23) and, until May 2011, 730 patients had undergone 
such procedure (24). A number of countries, such as 
Canada, Switzerland, Australia, Japan, England and 
Belgium, already consider islet transplantation to be an 
acceptable treatment option for patients with “brittle 
T1DM”. In these countries, such procedure is cov-
ered by public and/or private health services (25,26). 
However, in many other countries, including USA, is-
let transplantation is still performed on an experimen-
tal basis (phase 3 clinical trials) (27). In the USA, islet 
transplantation is expected to be approved as a treat-
ment option for “brittle T1DM” in 2015, following 
the end of a large multicenter clinical trial, which is cur-
rently being evaluated by the Food and Drug Admin-
istration (FDA).
Islet transplantation has led to progressively better 
results over recent years. A recent CITR report assessed 
the outcomes of 677 patients who had undergone is-
let transplantations between the years 1999 and 2010. 
Patients were divided into three groups according to 
the period their surgeries were performed: “Early Era” 
(1999-2002), “Mid Era” (2003-2006) and “Recent 
Era” (2007-2010). Five main outcomes were assessed: 
presence of C-peptide secretion, decrease in HbA1c 
levels, stable fasting glycemia, insulin independence 
and frequency of severe hypoglycemia (11). Patients 
who underwent transplantations in the “Recent Era” 
had significantly better outcomes, and achieved an in-
sulin independence rate of almost 50% three years after 
the transplant (11,24). This result may be attributed 
to the improvement of islet isolation and islet culture 
techniques, as well as to the improvement of immu-
nosuppressive regimens, more careful patient selection 
and increased knowledge and understanding of β cell 
characteristics and requirements (11). The latest data 
obtained for graft survival at 5 years after islet trans-
plantation have shown a significant increase in insulin 
independence rate. In some studies, 70% of insulin in-
dependence has been achieved in 7 years of follow-up, 
so far (28). These numbers are similar to those achieved 
with pancreas transplant alone in the same period (29). 
A search for open trials on the Clinical Trials website 
(www.clinicaltrials.gov), performed in January 2014 
using the keyword “islet transplantation”, identified 34 
studies which are currently recruiting patients for such 
procedure. These studies include investigations of im-
munosuppressive drugs following allogeneic islet trans-
plantation, the outcomes of encapsulated islet trans-
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plantations and the applicability of autologous islet 
transplantation in cases of total pancreatectomy. None 
of these investigations are currently being conducted in 
South America. At the time of writing this paper, the 
Islet Transplant Program at the University of Greno-
ble, France, is conducting the first randomized clinical 
trial to compare the outcomes of islet transplantation 
with those on standard clinical treatment for T1DM 
(TRIMECO, http://clinicaltrials.gov).
ISOLATION OF HUMAN PANCREATIC ISLETS
The process of islet isolation involves the extraction of 
insulin-producing cells from the pancreas, while pre-
serving their structural and functional integrity (30). 
Islet isolation methods have become increasingly so-
phisticated over the past three decades (7) and advances 
in this area are at least partly attributable to the use of 
a semi-automated method of controlled pancreatic di-
gestion developed by Camillo Ricordi in 1989 (19). 
Although this islet isolation protocol has been slightly 
modified over recent years, according to the experience 
of different transplantation groups, the basic steps of the 
procedure remain the same: cleaning the pancreas and 
cannulation of pancreatic ducts, enzymatic perfusion, 
distension and digestion of the pancreas, followed by 
islet dilution, purification and culture (Figure 2) (31).
The process starts when the donated organ is re-
ceived and assessed by an isolation team, and ends with 
the release of the isolated islets for transplantation or 
research by a quality control (QC) team. The first stage 
of the process is the cleaning of the pancreas, which 
consists in organ dissection and removal of the spleen, 
duodenum and any underlying fat. The next step con-
sists of pancreatic distension and digestion, a process 
through which an enzyme which breaks up collagen 
chains (collagenase) is infused into the main pancreatic 
duct, leading to the disaggregation of the pancreatic 
tissue. The pancreas is then cut into 8 to 10 pieces and 
transferred to a Ricordi Chamber (19) containing 7-9 
silicone beads and filled with collagenase solution for 
the digestion phase, which is facilitated by mechanical 
agitation. When islets are separated from the exocrine 
tissue and are not over-digested, large volumes of dilu-
tion solution are then added to the tissue to stop the 
digestion process. In the purification step, the islets are 
separated from the exocrine and ductal tissues through 
continuous or discontinuous density gradients using a 
COBE 2991 centrifuge. The goal of this step is to puri-
fy the islets that will be used in the transplant, throwing 
Figure 2. Pancreatic islet isolation and transplantation from the donor to the recipient. Adapted from reference 31. 1 = sampling location for islet collection 
and for the monitoring of digested islets; 2 = chamber temperature monitoring probe (37°C); 3 = Ricordi Chamber with silicone beads, pancreatic tissue 
and collagenase solution; 4 = peristaltic pump to ensure the circulation of the solutions in the system; 5 = heating coil in a 50°C water bath. 
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away the remaining cells, so that only a small volume of 
tissue (10 mL maximum) will be infused into the portal 
vein, reducing the risk of portal vein hypertension and 
thrombosis (16). After isolation, islets are cultured for 
up to three days (32).
The FDA has stated that, before allogeneic islet 
transplantation is approved as a treatment option for 
T1DM, the safety, purity, potency and efficacy of the 
islets must be assessed. For islets to be considered suit-
able for transplantation, the islet isolation and purifica-
tion processes must be defined, validated, and proved to 
be able to generate consistently high-quality products 
(33). Therefore, the last step in the isolation process 
consists of QC tests for purity, number of islet equiva-
lents (IEQ – one IEQ corresponds to one islet with 
150 μm diameter or greater), viability, cell functionality 
and sterility (34).
Purity (the proportion of islets to other tissue types 
in the isolated material) is assessed throughout the 
stages of islet isolation and culture. Only the samples 
with purity > 50% can be approved for transplant. The 
IEQ is determined by the estimated diameter of islets. 
Transplantation is only possible if the IEQ is > 5000 
IEQ/kg of the recipient’s body weight, in a maximum 
volume of 5-10 mL (34). The viability of islets (num-
ber of live cells/total number of cells, including dead 
cells) is determined by the integrity of the cell mem-
brane. This is assessed by staining tissue samples with 
two types of dye (fluorescein diacetate, which stains 
viable cells green, and propidium iodide, which stains 
damaged cells red), and examining the results in a fluo-
rescent microscope (35). The islet batch is considered 
adequate for transplantation if its viability is over 80%. 
Islet function is assessed by measuring the amount of 
insulin secreted after incubation with low and high 
concentrations of glucose and, then, calculating a stim-
ulation index (SI) by dividing insulin concentration of 
the islet sample stimulated with high glucose by the in-
sulin concentration of the islet sample stimulated with 
low glucose (20). Functional islets must have a SI > 1. 
The sterility is assessed through aerobic and anaerobic 
bacterial cultures as well as mycoplasma and endotoxin 
tests (16,34).
ISLET TRANSPLANTATION AND THE CURRENT 
STATUS OF THIS PROCEDURE IN BRAZIL
Pancreatic islet transplantations have proved to be a 
safe and effective treatment option for patients with 
“brittle T1DM”. However, the clinical applicability of 
islet transplantation in many health centers is limited by 
the complexity of islet isolation processes, the high cost 
(34,36) and the scarcity of donor organs (37). Since 
each transplant patient generally requires islets isolated 
from two to three donors in order to improve rates of 
insulin independence (37), there is a significant interest 
in developing methods for isolating the greatest num-
ber of viable islets from the pancreas of each donor. 
However, this is a challenging process, which requires 
considerable experience with cell isolation procedures 
and an extensive knowledge of the factors which influ-
ence islet quantity and quality (38). 
The physical, chemical and mechanical impacts suf-
fered by the islets during the isolation process might 
lead to fragmentation and damage of the β, α, δ and PP 
cells (39), influencing the quantity and quality of avail-
able islets. In the past 6 years, an additional obstacle 
was introduced into islet isolation research, as the most 
effective collagenase used in pancreatic digestion (Lib-
erase HI, Roche Pharmaceutics) was removed from 
the market due to the discovery of an association be-
tween the enzyme and an increased risk of spongiform 
encephalopathy transmission (40). Other collagenases, 
such as Serva NB1 (Serva, Heidelberg, Germany), 
Liberase MTF (Roche, Indianapolis, USA) and Vita-
cyte (CIzyme HA, Indianapolis, USA) (37,41-43) are 
promising alternatives for islet isolation (44). However, 
studies that have sought to assess which enzyme would 
be the most adequate for pancreatic digestion have 
produced conflicting results (40,42,45-48). A meta-
analysis conducted by our research group (49) found 
that all aforementioned enzymes lead to similar levels of 
islet quantity (IEQ/g pancreas) and quality (purity and 
viability); however, Vitacyte and Serva NB1 enzymes 
seem to be associated with an improved SI as compared 
with Liberase MTF. 
Donor characteristics (age, gender, medical history, 
body mass index [BMI], cause of death, use of vasopres-
sor agents) and pancreas characteristics (size, fat con-
tent, duration of cold ischemia) may also influence the 
quality and quantity of the isolated islets (30,50,51). 
Although organs donated by individuals with BMI > 
25 kg/m2 and/or age over 50 years tend to produce 
a greater number of islets, these islets do not always 
function adequately (50,51). The study by Sá and cols. 
(53) reinforced the importance of the donor BMI as 
a defining parameter for successful islet isolation and 
established this variable as a potential pancreas alloca-
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tion criterion for pancreatic islet transplantation in Bra-
zil. The duration of cold ischemia is also relevant to 
the islet isolation process, since increased cold ischemia 
time may damage the pancreatic tissue. Therefore, the 
type of solution used to preserve the pancreas and de-
crease the deleterious effects of hypoxia may have an 
important effect on transplant results (30). Most isola-
tion procedures involve the use of the UW (University 
of Wisconsin) solution, which contains electrolytes and 
other substances that contribute to cell integrity (30). 
However, some studies have found that the combined 
use of UW solution and other substances with high ox-
ygen affinity (two-layer perfluorocarbon method) led 
to improved pancreatic preservation (54,55), although 
these results were most pronounced in cases of pro-
longed cold ischemia (56). 
The effect of brain death (BD) on the pancreas may 
also influence the quality of the donated organ. A study 
conducted by our research group found that, in the 
case of BD donors, the pancreas appears to be damaged 
long before isolation, as evidenced by an increase in 
TNF levels in the organ (57). Another recent study has 
also found that the organs of BD donors produce islets 
of lower quality when compared to those whose donors 
died of heart-related causes (51). 
As previously cited, one of the main limitations re-
ported by most islet transplantation centers is a scar-
city of BD donors (8). In Brazil, a report issued by the 
Brazilian Organ Transplant Association noted that only 
6.3% (n = 80) of the total number of pancreases donat-
ed (n = 1273) were used in the first semester of 2013 
(58). The remaining organs could have been used for 
islet isolation purposes, indicating an adequate supply 
of organs for islet transplantation in Brazil. In Brazil, 
there are two laboratories involved in islet isolation 
research, which, in the past, had also carried out islet 
transplants: the NUCEL (Nucleus of Cell and Molecu-
lar Therapy) in São Paulo, which is associated with the 
University of São Paulo (USP) and performed its first 
transplant in 2002 (59); and a laboratory in Curitiba 
(Paraná), associated with the PUC-Paraná University 
and the Pro-Kidney Foundation, which conducted one 
transplant in 2005 (60). 
Nevertheless, the high costs involved in islet iso-
lation still place a burden on this process. In 2004, a 
French study evaluated the cost of islet transplanta-
tion from the time of organ removal until the trans-
plant itself and its follow-up. The study found that islet 
isolation was the most expensive phase of the process, 
accounting for 30% of total transplant costs (36). A 
similar situation has been reported in Brazil, where the 
reliance on imported isolation reagents may lead costs 
to rise even further (61). 
In light of these facts, a number of islet transplanta-
tion centers have focused on the development of differ-
ent methods for islet isolation and, when possible, for 
the selection of organs that might be more adequate 
for transplantation and are more likely to produce posi-
tive results in terms of the quantity and quality of iso-
lated islets and insulin independence in the long term 
(37,57,60). 
BRAZILIAN LEGISLATION
In the USA, the islet isolation process must follow the 
drug and biological product regulations issued by the 
FDA and the Public Health Service Act (62). In Bra-
zil, there is still no specific legislation to regulate islet 
transplantation. However, both the construction of 
the isolation laboratories as well as the islet isolation 
process must follow RDC Resolutions Numbers 210 
(“Good Practice in Drug Manufacturing”, August 4th, 
2003) and 9 (“Guidelines for the functioning of Cell 
Technology Centers involved in clinical research and 
treatment”, March 14th, 2011) issued by the Agência 
Nacional de Vigilância Sanitária (Anvisa) (63,64). RDC 
resolution number 9 divides cell therapy methods into 
two categories according to their purpose: autologous 
use and allogeneic cell manipulation. Islet transplan-
tation procedures would be classified into the latter 
group. 
ISLET TRANSPLANTATION IN PATIENTS WITH 
“BRITTLE T1DM”
Islet transplantation is generally recommended as a treat-
ment option for patients with “brittle T1DM”, which 
is defined by the presence of significant daily variations 
in capillary glycemia, typically higher than 200 mg/dL, 
which might lead to significant impairment in quality 
of life and/or the occurrence of severe hypoglycemia 
without adrenergic symptoms (6,65). In these patients, 
allogeneic islet transplantation tend to be performed in 
one of three ways depending on patient characteristics: 
1) islet transplantation in non-uremic patients; 2) islet 
transplantation following kidney transplants in patients 
with end-stage kidney disease; and 3) simultaneous islet 
and kidney transplantations (66). 
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To date, patients included in islet transplantation 
protocols have had the following characteristics: age be-
tween 18 and 65 years, T1DM for over 5 years with un-
detectable C-peptide concentrations, occurrence of se-
vere recurrent hypoglycemia and progression of chronic 
complications associated with diabetes (30). In the Im-
mune Tolerance Network study (22), the presence of 
untreated arterial disease, BMI > 26 kg/m2, the need 
for insulin doses > 0.7 UI/kg, HbA1c > 12%, creatinine 
> 1.5 mg/dL and/or albuminuria > 300 mg/24h, as 
well as the presence of infections or psychiatric diseases 
were considered exclusion criteria for transplantations. 
In islet transplantations, as in pancreas transplants, 
the persistence or reappearance of anti-islet antibo dies 
has been found to be correlated with worse clinical out-
comes and may be a key contributing factor to graft 
failure (67). However, patient characteristics may also 
influence transplant outcome. Younger patients with 
higher HbA1c levels, clinical profiles suggestive of in-
sulin resistance and higher lipid serum levels in the pre-
transplant period are at greater risk of early graft loss 
(68,69). 
It is also important to note that the site of islet 
infusion used by most studies in the literature is the 
portal vein, which is not the most adequate place for 
cell infusion (70). It is estimated that 50-70% of islets 
are destroyed in the period immediately following the 
transplant, given the unique characteristics of the liver 
and the damaging effect of immunosuppressive drugs 
on insulin secretion and islet viability (71). Currently, 
other infusion sites and methods have been studied in 
an attempt to develop techniques that ensure a better 
engraftment of the islets. One example is the encapsu-
lation, which allows for revascularization while sparing 
the islets from environmental damage (70).
DEVELOPMENT OF A HUMAN ISLET ISOLATION 
LABORATORY IN THE HCPA
In 2010, a new laboratory for human islet isolation was 
established at the Endocrine Division of HCPA with 
the goal of isolating islets for: 1) developing experi-
mental studies to assess ways of increasing the quality 
and quantity of isolated islets; 2) studying functional β 
cells in patients with different physiological and patho-
logical features; and 3) performing islet transplanta-
tion in patients with “brittle T1DM”. This center has 
conducted 28 human islet isolations and, in the near 
future, will begin a study of human islet transplantation 
in T1DM patients who had already undergone kidney 
transplantation.
This islet isolation laboratory takes up an area of 
63.6 m2 in the Endocrine Division (Figure 3). The lab-
oratory was built between 2008 and 2010, and its con-
struction process followed the guidelines established 
in RDC regulations (numbers 134 and 210) issued by 
Anvisa (63), as well as recommendations provided by 
the islet transplantation team at the Diabetes Research 
Institute, University of Miami (EUA). 
Positive internal pressure, use of air-conditioning 
with high efficiency particulated air (HEPA) filters, and 
restricted access policies in effect at the islet isolation 
laboratory are the same as those recommended for sur-
gery rooms. The dressing room is kept at cleanliness 
Class 100.000 (up to 100.000 particles with a size of 
0.5 microns or greater per m3 of air), while the remain-
der of the lab is kept at Class 10.000. The laboratory 
contains a dressing room for changing into sterile gar-
ments, a hand-rubbing area, a separate internal loca-
tion for islet isolation and culture, a reagent storage 
room, a cold chamber and a laboratory exit chamber. 
All furniture in the laboratory is made of stainless steel 
to facilitate cleaning and prevent contamination. The 
laboratory is surrounded by a Cell and Molecular Bi-
ology Laboratory, a glassware sterilization room, and 
the QC center for the isolated islets, which contains a 
fluorescent microscope and an ELISA (enzyme-linked 
immunosorbent assay) micro-plate reader. 
The core of the islet isolation team consists of a ne-
phrologist and a biologist, both of whom are HCPA em-
ployees who received training in international re ference 
centers. The nephrologist held her training in isolation 
of human, pig and mouse islets as well as in human islet 
transplantation at the Schulze Diabetes Institute (Uni-
versity of Minnesota, Minneapolis, EUA) for two years, 
while the biologist was trained in rat islet isolation and 
β cell functionality at the Laboratory of Experimental 
Medicine of the Free University of Brussels (Brussels, 
Belgium) for one year. The team also includes an en-
docrinologist, who was trained in human islet isolation 
as well as monitoring and treatment of transplanted pa-
tients at the Diabetes Research Institute of the Universi-
ty of Miami (Florida, EUA) for a period of one year. The 
islet isolation team is assisted by undergraduate students, 
masters’ and PhD students, a technical support assistant 
and a post-doctoral fellow, all of whom received scholar-
ships from national research support agencies. A research 
project entitled “Establishment of a Human Pancreatic 


















168 Arch Endocrinol Metab. 2015;59/2
Islet Isolation Laboratory at the HCPA” was developed 
specifically for the purpose of constructing the laborato-
ry and organizing an organ donation system. This proj-
ect was approved by the Research Ethics Committee of 
HCPA (project number 08-131) and by the Transplant 
Center of the state of Rio Grande do Sul, Brazil. Any 
donated organs which are not used for whole-pancreas 
transplants or kidney-pancreas transplantation are used 
for islet isolation purposes once the donor’s family signs 
an informed consent form provided by the Laboratory 
of Human Pancreatic Islet Biology. The surgical team re-
sponsible for organ removal is associated with the OPOS 
(Organ Procurement Organizations) of the Department 
of Health – Rio Grande do Sul. 
Figure 3. Floorplan of the Laboratory of Human Pancreatic Islet Biology – Endocrine Division – Hospital de Clínicas de Porto Alegre. 1 = Biological safety 
cabinets; 2 = Incubators; 3 = Freezer -86°C; 4 = Refrigerator; 5 = Freezer -20°C; 6 = Water bath; 7 = Microscope; 8 = COBE 2991; 9 = Door with 
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CONCLUSIONS 
Pancreatic islet transplantation should be considered 
a useful treatment option for decreasing the occur-
rence of severe hypoglycemic episodes and improving 
glycemic control in patients with “brittle T1DM”. In 
many countries, islet transplantation is already used as 
treatment for T1DM. However, in countries such as 
Brazil, this procedure is still carried out only as part 
of experimental research initiatives. Therefore, efforts 
must be made toward increasing the effectiveness of 
islet isolation and transplantation techniques, as well 
as post-transplant follow-up procedures, to ensure that 
islet transplantation will be eventually implemented as 
part of routine clinical practice.
The establishment of islet isolation laboratories is a 
slow and complex process, which requires significant 
financial investment. The Laboratory of Human Pan-
creatic Islet Biology at the Endocrine Division of the 
HCPA aims to provide human islets for research pur-
poses and, in the near future, become a reference center 
for islet transplantation and β cell research in Brazil.
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